Table 3.

Current practices that organizations conducting HIV vaccine trials use to address VISR^‡

Survey question	# of organizations answering YES
Inform participants of the potential for VISR and how it may impact their lives
The protocol informed consent describes VISR and associated risks	9
Provide accurate testing for former trial participants who have VISR
End of study HIV testing to asses risk of VISR, performed with locally available tests	9
Post-study differential VISR vs. HIV infection testing provided as long as needed	9
Participants who relocate can access VISR vs. HIV infection testing remotely	5
A long-term mode for contact is provided in the event that CRS closes	7
Help manage any social harms that occur as a result of the participant's VISR status
The protocol collects laboratory data on VISR	9
The protocol collects data on VISR related social impact	5
Post-study enrollment in long-term follow up study offered	5
Assistance is provided to participants with VISR in regards to social harms	9
Research staff maintains records with identifiers and study regimen of participants who may need support with VISR related issues	9 2 Registries
Inform scientists, health care providers, and the community about the existence of VISR
Information about VISR was presented at meetings attended by investigators and healthcare practitioners	8
Data about VISR was published in scientific journals	7
In-country blood banks have been informed about VISR	5

^‡Survey conducted by NIAID and the Global HIV Vaccine Enterprise (2013-2014). Organizations participating: ANRS: Agence Nationale de Recherche sur le SIDA- Vaccine Research Institute, France; China CDC: Chinese Center for Disease Control, China; EDCTP: European and Developing Countries Clinical Trials Partnership, The Netherlands; IAVI: International AIDS Vaccine Initiative, US; HVTN: HIV Vaccine Trials Network, US; UK HVC: HIV Vaccine Consortium, UK; US MHRP: Military HIV Research Program, US.